PhD, Associate Researcher, Overseas High-Level Talent in Shenzhen, Talent of Excellence in Futian District, Deputy Researcher at Shenzhen Second People's Hospital. Currently serving as a committee member of the Neuro-Oncology Specialty Committee of Shenzhen Anti-Cancer Association and the Brain Metastasis Specialty Committee of China Anti-Cancer Alliance Shenzhen League. Obtained PhD degree from The Hong Kong Polytechnic University in 2015. Conducted postdoctoral research from 2015 to 2018 at Shenzhen Second People's Hospital (affiliated station) / Sun Yat-sen University (roving station).

Currently engaged in foundational and clinical translational research on molecular targeted therapy for glioblastoma, leading the management of the "Shenzhen Medical Management Center Medical Science and Technology Innovation Platform - Key Technology Research and Clinical Application Platform for Brain Tumor Precision Medicine". Research interests primarily focus on molecular targeted therapy and combination drug therapy for recurrent gliomas, employing multi-omics analysis techniques to elucidate the molecular mechanisms of glioma recurrence and cell invasion.

Principal investigator of 7 national and provincial-level funding projects, including 1 National Natural Science Foundation of China (Youth Fund), 2 Guangdong Natural Science Foundation (General Program), 1 China Postdoctoral Science Foundation, 1 Shenzhen Basic Research Project of Science and Technology Innovation Committee, and 2 open topics from the State Key Laboratory of Oncology in South China. Published 17 SCI papers in journals such as Molecular Cancer, J Exp Clin Cancer Res, and Cancer Cell Int, with a total impact factor of approximately 62.14. First author or corresponding author for 10 SCI papers.

July 2012 - September 2015 The Hong Kong Polytechnic University, School of Medical and Health Sciences, Department of Medical Sciences and Informatics PhD in Medical Technology and Information Advisor: To Shing Shun Tony

September 2005 - June 2007 Sun Yat-sen University, School of Life Sciences, Department of Zoology Master of Science Advisor: Zhang Wenqing

September 2001 - June 2005 Wuhan University, School of Life Sciences, Department of Biological Sciences Bachelor of Science

April 2018 - Present Shenzhen Second People's Hospital, Institute of Translational Medicine Associate Researcher

October 2015 - March 2018 Shenzhen Second People's Hospital Postdoctoral Researcher

August 2008 - June 2012 Medical Experimental Department, Guangzhou General Hospital of Guangzhou Military Region Research Assistant, Key Laboratory of Orthopedic and Implant Materials of Guangdong Province

National Natural Science Foundation of China, Young Scientists Fund Project, 81602195, Mechanism of PI3Kβ-JNK mediated FAK-vinculin regulation of glioblastoma cell adhesion plaque assembly and cell migration, January 2017 - December 2019, 170,000 RMB, Completed, Principal Investigator.

Guangdong Natural Science Foundation, Basic Research Project, 2021A1515012143, Mechanism study of PI3Kβ and MLK3 inhibitor-chitosan nanohydrogel-neutrophil drug delivery system synergistically inhibiting malignant glioma recurrence after surgery, January 2021 - December 2023, 100,000 RMB, Ongoing, Principal Investigator.

Guangdong Natural Science Foundation, Free Application Project, 2017A030313531, Mechanism study of LanCL2 mediated Src-Tks5/cortactin signaling axis in regulating glioblastoma invadopodia assembly and formation, May 2017 - May 2020, 100,000 RMB, Completed, Principal Investigator.

China Postdoctoral Science Foundation, General Project, 2016M592588, Mechanism study of PI3Kβ synergizing with JNK in regulating glioma cell proliferation and migration, May 2016 - March 2018, 50,000 RMB, Completed, Principal Investigator.

Shenzhen Science and Technology Innovation Committee, Basic Research Project, JCYJ20160425104157183, Mechanism study of MLK3 synergizing with PI3Kβ in regulating glioblastoma adhesion turnover and cell migration, August 2016 - July 2019, 210,000 RMB, Completed, Principal Investigator.

State Key Laboratory of Oncology in South China, Open Project, HN2016-09, Mechanism study of MLK3 synergizing with PI3Kβ through FAK-paxillin in regulating glioblastoma adhesion turnover and cell migration, June 2016 - June 2017, 50,000 RMB, Completed, Principal Investigator.

State Key Laboratory of Oncology in South China, Open Project, HN2018-11, Mechanism study of LanCL2 mediating MARCKS phosphorylation in regulating glioblastoma invasive pseudopodia formation, December 2018 - December 2019, 50,000 RMB, Completed, Principal Investigator.

1.Zhao HF^#, Zhou XM^#, Wang J, Chen FF, Wu CP, Diao PY, Cai LR, Chen L, Xu YW, Liu J, Li ZY, Liu WL, Chen ZP, Huang GD*, Li WP*. Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients. J Transl Med. 2021;30;19(1):372. (IF=5.531)

2.Zhao HF^#, Wu CP^#, Zhou XM, Diao PY, Xu YW, Liu J, Wang J, Huang XJ, Liu WL, Chen ZP, Huang GD, Li WP*. Synergism between the phosphatidylinositol 3-kinase p110β isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation. Cancer Cell Int. 2021;21(1):24. (IF=5.722)

3.Zhao HF, Wang G, Wu CP, Zhou XM, Wang J, Chen ZP, To ST*, Li WP*. A multi-targeted natural flavonoid myricetin suppresses lamellipodia and focal adhesions formation and impedes glioblastoma cell invasiveness and abnormal motility. CNS Neurol Disord Drug Targets. 2018;17(7):557-567. (IF=2.761)

4.Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To SST*, Li WP*. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Molecular Cancer. 2017; 16(1):100. (IF=7.776)

5.Zhao HF^#, Wang J^#, Jiang HR, Chen ZP*, To SS*. PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition. J Exp Clin Cancer Res. 2016; 35(1):78. (IF=5.189)

6.Zhao HF, Wang J, To SST*. The phosphatidylinositol 3-kinase/Akt and c-Jun N-terminal kinase signaling in cancer: alliance or contradiction? (review). Int J Oncol. 2015; 47(2): 429-436. (IF=3.018)

7.Zhao HF, Li M, Li LM, Yang XM, Lan GB, Zhang Y*. MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis. PloS one. 2013; 8(12):e83571. (IF=3.5328)

8.Wu CP^#, Wu P^#, Zhao HF^#（共同一作）, Liu WL*, Li WP*. Clinical applications of and challenges in single-cell analysis of circulating tumor cells.DNA & Cell Biology. 2018; 37(2):78-89. (IF=2.918)

9.Wang W^#*, Zhao HF^#（共同一作）, Yao TF, Gong H. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment. Invest New Drugs. 2019;37(1):175-183. (IF=3.534)

10.Wu J^#, Su HK^#, Yu ZH^#, Xi SY, Guo CC, Hu ZY, Qu Y, Cai HP, Zhao YY, Zhao HF, Chen FR, Huang YF, To STT, Feng BH, Sai K*, Chen ZP*, Wang J*. Skp2 modulates proliferation, senescence and tumorigenesis of glioma. Cancer Cell Int. 2020; 20:71.(IF=4.175)

11.Xu YW^#, Liao CP^#, Liu RL^#, Liu J, Chen ZP, Zhao HF, Li ZY, Chen L, Wu CP, Tan H, Liu WL*, Li WP*. IRGM promotes glioma M2 macrophage polarization through p62/TRAF6/NF-κB pathway mediated IL-8 production. Cell Biol Int, 2019;43(2):125-135.

12.Xu YW^#, Liu RL^#, Liao CP^#, Liu J, Zhao HF, Li ZY, Liu WL, Chen L, Wu CP, Tan H, Chen ZP, Xie N*, Li WP*. High expression of immunity-related GTPase family M protein in glioma promotes cell proliferation and autophagy protein expression.Pathol Res Pract. 2019; 215(1):90-96.

13.Liu J^#, Zhou Q^#, Wu CP^#, Xu YW, Liu WL, Zhao HF, Li WP*. SPHK2 protein expression, Ki-67 index and infiltration of tumor-associated macrophages (TAMs) in human glioma. Histology And Histopathology, 2018, 33(9): 987-994.

14.Wang J, Su HK, Zhao HF, Chen ZP*, To ST*. Progress in the application of molecular biomarkers in gliomas. BBRC. 2015; 465(1):1-4. (IF=2.371)

15.Wang J, Zhao YY, Li JF, Guo CC, Chen FR, Su HK, Zhao HF, Long YK, Shao JY, To SST*, Chen ZP*. IDH1 mutation detection by droplet digital PCR in glioma. Oncotarget. 2015; 6(37):39651-60. (IF=5.0079)

16.Wang G*, Wang JJ, Wu W, Tony To SS, Zhao HF, Wang J. Advances in lipid-based drug delivery: enhancing efficiency for hydrophobic drugs. Expert Opin Drug Deliv. 2015; 5:1-25. (IF=5.434)

17.Wang G*, Wang JJ, Zhao HF, Wang J, Tony To SS. The role of Myc and let-7a in glioblastoma, glucose metabolism and response to therapy. Arch Biochem Biophys. 2015;580:84-92. (IF=2.8069)

18.Wang G*, Wang JJ, To SST, Zhao HF, Wang J. Role of SIRT1-mediated mitochondrial and Akt pathways in glioblastoma cell death induced by Cotinus coggygria flavonoid nanoliposomes. Int J Nanomedicine, 2015; 10: 5005-5023. (IF=4.32)

王刚，王俊杰，赵华福，李菲，杜丽，关锐。具有调控糖代谢途径关键靶点的黄酮及其递药系统抗胶质瘤作用机制，上海市药学会，上海药学科技奖三等奖，2019。